JP2022528780A5 - - Google Patents
Info
- Publication number
- JP2022528780A5 JP2022528780A5 JP2021560707A JP2021560707A JP2022528780A5 JP 2022528780 A5 JP2022528780 A5 JP 2022528780A5 JP 2021560707 A JP2021560707 A JP 2021560707A JP 2021560707 A JP2021560707 A JP 2021560707A JP 2022528780 A5 JP2022528780 A5 JP 2022528780A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- compound according
- inhibitors
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833364P | 2019-04-12 | 2019-04-12 | |
| US62/833,364 | 2019-04-12 | ||
| PCT/US2020/027453 WO2020210481A1 (en) | 2019-04-12 | 2020-04-09 | Heterocyclic compounds as kinase inhibitors for therapeutic uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022528780A JP2022528780A (ja) | 2022-06-15 |
| JP2022528780A5 true JP2022528780A5 (cg-RX-API-DMAC7.html) | 2023-04-17 |
| JP7568641B2 JP7568641B2 (ja) | 2024-10-16 |
Family
ID=72751520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560707A Active JP7568641B2 (ja) | 2019-04-12 | 2020-04-09 | 治療的使用のためのキナーゼ阻害剤としての複素環式化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12668584B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3952865A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7568641B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102913995B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114025755B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020271855B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132855A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI757722B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020210481A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| CA3156828A1 (en) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Tricyclic kinase inhibitors and uses thereof |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| EP4267574B1 (en) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CN114031561B (zh) * | 2021-12-10 | 2022-12-02 | 江西科技师范大学 | 含4-苯氧基喹唑啉类化合物及其应用 |
| KR102910577B1 (ko) * | 2022-02-17 | 2026-01-08 | 내셔날 헬스 리서치 인스티튜트 | 융합 다환식 화합물의 제조 방법 |
| CN116763787A (zh) * | 2022-03-08 | 2023-09-19 | 安徽中科拓苒药物科学研究有限公司 | 喹啉类化合物的新用途 |
| TW202448857A (zh) * | 2023-05-12 | 2024-12-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有芳香二並環的化合物 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298311B1 (en) * | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| HU230863B1 (hu) * | 1999-01-13 | 2018-10-29 | Bayer Healthcare Llc | Omega-karboxi-arilcsoporttal helyettesített difenil-karbamidok, mint raf-kináz inhibitorok |
| IL144461A0 (en) | 1999-01-22 | 2002-05-23 | Kirin Brewery | Quinoline and quinazoline derivatives and pharmaceutical compositions containing them |
| KR100600550B1 (ko) * | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| JP4383870B2 (ja) | 2001-10-17 | 2009-12-16 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| AP2006003619A0 (en) | 2003-12-23 | 2006-06-30 | Pfizer | Novel quinoline derivatives |
| GB0509224D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법 |
| AU2008254425A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| CN101372475B (zh) * | 2008-03-19 | 2012-01-04 | 南京工业大学 | 芳杂环取代的二苯脲类衍生物及其用途 |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| KR101106050B1 (ko) | 2009-03-25 | 2012-01-18 | 한국과학기술연구원 | 아미노퀴놀린 화합물, 이의 제조 방법 및 이를 함유하는 의약 조성물 |
| CN101671301B (zh) * | 2009-05-05 | 2014-02-26 | 江苏省药物研究所有限公司 | 杂环取代的二苯脲类衍生物及其用途 |
| US9358235B2 (en) * | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| BR112015022263B1 (pt) | 2013-03-15 | 2023-01-03 | Deciphera Pharmaceuticals Llc | N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica |
| CN104177346A (zh) | 2013-05-21 | 2014-12-03 | 苏州科捷生物医药有限公司 | 喹唑啉类化合物及其用途 |
| SG10201408115SA (en) | 2014-12-05 | 2016-07-28 | Chakra Biotech Pte Ltd | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders |
| WO2016161952A1 (zh) | 2015-04-07 | 2016-10-13 | 广东众生药业股份有限公司 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| HK1255102A1 (zh) * | 2015-09-21 | 2019-08-02 | Plexxikon Inc. | 杂环化合物及其应用 |
| US10160747B2 (en) * | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| SG11201903091VA (en) | 2016-10-10 | 2019-05-30 | Dev Ct Biotechnology | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |
| WO2018081276A1 (en) | 2016-10-25 | 2018-05-03 | Tesaro, Inc. | Compounds |
-
2020
- 2020-04-09 AU AU2020271855A patent/AU2020271855B2/en active Active
- 2020-04-09 KR KR1020217032764A patent/KR102913995B1/ko active Active
- 2020-04-09 JP JP2021560707A patent/JP7568641B2/ja active Active
- 2020-04-09 US US17/603,273 patent/US12668584B2/en active Active
- 2020-04-09 CN CN202080024676.8A patent/CN114025755B/zh active Active
- 2020-04-09 EP EP20787959.4A patent/EP3952865A4/en active Pending
- 2020-04-09 WO PCT/US2020/027453 patent/WO2020210481A1/en not_active Ceased
- 2020-04-09 CA CA3132855A patent/CA3132855A1/en active Pending
- 2020-04-10 TW TW109112137A patent/TWI757722B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI844568B (zh) | 抑制shp2活性化合物之製造方法、及由酸加成產生之產物 | |
| JP2019512505A5 (cg-RX-API-DMAC7.html) | ||
| KR102534028B1 (ko) | 트리아졸로피리미딘 화합물 및 그의 용도 | |
| ES2923875T3 (es) | Moduladores de la vía integrada del estrés | |
| US12139494B2 (en) | Morphic forms of G1T38 and methods of manufacture thereof | |
| TWI757722B (zh) | 以雜環化合物作為激酶抑制劑的治療用途 | |
| ES2439776T3 (es) | Triazolopiridinas sustituidas | |
| US12534472B2 (en) | Morphic forms of trilaciclib and methods of manufacture thereof | |
| JP2018537533A5 (cg-RX-API-DMAC7.html) | ||
| JP2014503567A5 (cg-RX-API-DMAC7.html) | ||
| JP7611154B2 (ja) | ピリド-ピリミジニル化合物及び使用の方法 | |
| JP2022517189A (ja) | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素i(ireiアルファ)の阻害剤としてのピリド-ピリミジノン化合物及びプテリジノン化合物 | |
| KR20140003436A (ko) | 과증식성 장애 및 혈관형성과 관련된 질환 치료에 유용한 아미노알코올 치환된 2,3-디하이드로이미다조[1,2-c]퀴나졸린 유도체 | |
| WO2018005533A1 (en) | Antiproliferative pyrimidine-based compounds | |
| JP2010531344A5 (cg-RX-API-DMAC7.html) | ||
| IL323777A (en) | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders | |
| AU2018350980A1 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors | |
| US12006320B2 (en) | Heterocyclic derivatives as PI3K inhibitors | |
| WO2021257587A1 (en) | Morphic forms of trilaciclib and methods of manufacture thereof | |
| ES2976576T3 (es) | Formas cristalinas de un inhibidor de la fosfoinositida 3-quinasa (pi3k) | |
| CA2955878A1 (en) | Amino-substituted isoxazoles | |
| WO2023141262A1 (en) | Bax activators and use thereof | |
| TW202304906A (zh) | 高活性hpk1激酶抑制劑 | |
| KR102549484B1 (ko) | 피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| CN121399105A (zh) | 杂芳族dhodh抑制剂 |